| Source: |
| Type: type of cell death |
| Situation in which a cell actively pursues a course toward death upon receiving certain stimuli. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die. |
| 1289- | FA, | Cytotoxic and Apoptotic Effects of Ferulic Acid on Renal Carcinoma Cell Line (ACHN) |
| - | in-vitro, | RCC, | NA |
| 1112- | FA, | Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | BC, | NA |
| 7513- | FA, | Anti-proliferative and anti-invasive effects of ferulic acid in TT medullary thyroid cancer cells interacting with URG4/URGCP |
| - | in-vitro, | Thyroid, | NA |
| 6862- | FBZ, | Research: The Urgent Need for Clinical Studies to Evaluate the Anti-Tumor Efficacy of Fenbendazole |
| - | Review, | Var, | NA |
| 6854- | FBZ, | Fenbendazole and its synthetic analog interfere with HeLa cells' proliferation and energy metabolism via inducing oxidative stress and modulating MEK3/6-p38-MAPK pathway |
| - | in-vitro, | Cerv, | HeLa |
| 6855- | FBZ, | Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study |
| - | vitro+vivo, | Ovarian, | A2780S | - | vitro+vivo, | Ovarian, | SKOV3 |
| 6858- | FBZ, | Fenbendazole and Diisopropylamine Dichloroacetate Exert Synergistic Anti-cancer Effects by Inducing Apoptosis and Arresting the Cell Cycle in A549 Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 |
| 2494- | FBZ, | Oral Fenbendazole for Cancer Therapy in Humans and Animals |
| - | Review, | Var, | NA |
| 6426- | FEO, | Foeniculum Vulgare and Pelargonium Graveolens Essential Oil Mixture Triggers the Cell Cycle Arrest and Apoptosis in MCF-7 Cells |
| - | in-vitro, | BC, | MCF7 |
| 6427- | FEO, | Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma |
| - | vitro+vivo, | HCC, | NA |
| 6428- | FEO, | Eug, | Triggering of apoptosis and cell cycle arrest by fennel and clove oils in Caco-2 cells: the role of combination |
| - | in-vitro, | Colon, | Caco-2 |
| 6891- | Fer, | Iron oxide nanoparticles inhibit tumor growth by ferroptosis in diffuse large B-cell lymphoma |
| - | vitro+vivo, | lymphoma, | NA |
| 6910- | FIS, | Exploring the therapeutic promise of fisetin: molecular mechanisms and clinical aspects in lung cancer |
| - | in-vitro, | Lung, | NA |
| - | in-vitro, | Cerv, | NA |
| 6911- | FIS, | New Mitochondria-Targeted Fisetin Derivative Compromises Mitophagy and Limits Survival of Drug-Induced Senescent Breast Cancer Cells |
| - | vitro+vivo, | BC, | NA |
| 6901- | FIS, | Fisetin induces G2/M phase arrest and caspase-mediated cleavage of p21Cip1 and p27Kip1 leading to apoptosis and tumor growth inhibition in HNSCC |
| - | in-vivo, | HNSCC, | CAL33 |
| 6900- | FIS, | Fisetin targets phosphatidylinositol-3-kinase and induces apoptosis of human B lymphoma Raji cells |
| - | in-vitro, | lymphoma, | NA |
| 6899- | FIS, | Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 |
| 6902- | FIS, | Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 2851- | FIS, | Apoptosis-induction-in-breast-cancer">Apoptosis induction in breast cancer cell lines by the dietary flavonoid fisetin |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | Nor, | NA |
| 2853- | FIS, | Fisetin Inhibits Cell Proliferation and Induces Apoptosis via JAK/STAT3 Signaling Pathways in Human Thyroid TPC 1 Cancer Cells |
| - | in-vitro, | Thyroid, | TPC-1 |
| - | in-vitro, | RCC, | Caki-1 |
| 2857- | FIS, | A review on the chemotherapeutic potential of fisetin: In vitro evidences |
| - | Review, | Var, | NA |
| 2844- | FIS, | Fisetin, a dietary flavonoid induces apoptosis via modulating the MAPK and PI3K/Akt signalling pathways in human osteosarcoma (U-2 OS) cells |
| - | in-vitro, | OS, | U2OS |
| 2826- | FIS, | Fisetin induces apoptosis in breast cancer MDA-MB-453 cells through degradation of HER2/neu and via the PI3K/Akt pathway |
| - | in-vitro, | BC, | MDA-MB-453 |
| 2829- | FIS, | Fisetin: An anticancer perspective |
| - | Review, | Var, | NA |
| 2839- | FIS, | Dietary flavonoid fisetin for cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2841- | FIS, | Fisetin, an Anti-Inflammatory Agent, Overcomes Radioresistance by Activating the PERK-ATF4-CHOP Axis in Liver Cancer |
| - | in-vitro, | Nor, | RAW264.7 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Liver, | HUH7 |
| 6990- | Form, | Formononetin induces apoptosis of human osteosarcoma cell line U2OS by regulating the expression of Bcl-2, Bax and MiR-375 in vitro and in vivo |
| - | vitro+vivo, | OS, | U2OS |
| 6980- | Form, | The potential role of formononetin in cancer treatment: An updated review |
| - | Review, | Var, | NA |
| 6982- | Form, | Formononetin: A Review of Its Anticancer Potentials and Mechanisms |
| - | Review, | Var, | NA |
| 6984- | Form, | Formononetin suppresses colitis-associated colon cancer by targeting lipid synthesis and mTORC2/Akt signaling |
| - | in-vitro, | Colon, | HCT116 | - | Review, | IBD, | RAW264.7 |
| 6986- | Form, | Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway |
| - | in-vitro, | NA, | NA |
| 6991- | Form, | Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 6970- | Form, | Formononetin, an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 6996- | Form, | MET, | Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro |
| - | in-vitro, | BC, | MCF7 |
| 6993- | Form, | ISL, | Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell |
| - | in-vitro, | CRC, | HCT116 |
| 6963- | Form, | Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D |
| 6966- | Form, | Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model |
| - | NA, | MM, | NA |
| 6969- | Form, | Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | HCC827 | - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 6977- | Form, | Differential ability of formononetin to stimulate proliferation of endothelial cells and breast cancer cells via a feedback loop involving MicroRNA-375, RASD1, and ERα |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HUVECs |
| 6971- | Form, | In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa |
| - | vitro+vivo, | Cerv, | HeLa |
| 6972- | Form, | PacT, | Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy |
| - | in-vivo, | BC, | MDA-MB-231 |
| 6973- | Form, | Formononetin enhances the chemosensitivity of triple negative breast cancer via BTB domain and CNC homolog 1-mediated mitophagy pathways |
| - | Human, | BC, | NA |
| 7010- | Fuc, | Fucoidan enhances the effect of chemotherapeutic drug against drug-resistant lung cancer cells |
| - | in-vitro, | Lung, | NA |
| 7011- | Fuc, | ATO, | VitA,RetA, | Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo |
| - | NA, | APL, | APL NB4 | - | vitro+vivo, | NA, | NA |
| 7013- | Fuc, | Fucoidan-based nanoparticles for colorectal cancer therapy: Mechanisms and preclinical insights |
| - | Review, | CRC, | NA |
| 7017- | Fuc, | Comparative study on neuroprotective activities of fucoidans from Fucus vesiculosus and Undaria pinnatifida |
| - | in-vitro, | AD, | PC12 |
| 7020- | Fuc, | Systematic synthesis of low-molecular weight fucoidan derivatives and their effect on cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | WI38 |
| 7022- | Fuc, | Antitumor Effects of Fucoidan on Human Colon Cancer Cells via Activation of Akt Signaling |
| - | in-vitro, | Colon, | HT29 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:14 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid